Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/32932
Title: | Treatment of hepatitis C with interferon and ribavirin. | Authors: | Pianko S. ;McHutchison J.G. | Institution: | (Pianko, McHutchison) Div. of Gastroenterology/Hepatology, Scripps Clin. and Res. Foundation, San Diego, CA, United States (McHutchison) Scripps Clin. and Res. Foundation, Div. of Gastroenterology/Hepatology, 10666 N Torrey Pines Road (203N), San Diego, CA 92037, United States (Pianko) Scripps Clinic and Research Found., Monash University, Monash Medical Centre, Victoria, Australia | Issue Date: | 19-Jul-2000 | Copyright year: | 2000 | Publisher: | Blackwell Publishing (E-mail: info@asia.blackpublishing.com.au) | Place of publication: | Australia | Publication information: | Journal of Gastroenterology and Hepatology (Australia). 15 (6) (pp 581-586), 2000. Date of Publication: 2000. | Journal: | Journal of Gastroenterology and Hepatology | Abstract: | Hepatitis C is a worldwide problem that frequently results in end-stage liver disease and its complications. Treatment for hepatitis C virus (HCV) has been rather ineffective but several recent studies have clarified the role of interferon and ribavirin therapy. In line with therapeutic progress in HIV infection, hepatitis C is now entering the era of multidrug antiviral therapy. Ribavirin is an orally active synthetic guanosine analogue with theoretical antiviral and immunomodulatory actions. In this review we have evaluated the role of interferon and ribavirin in treatment-naive patients, relapsers and non-responders. In naive patients the combination results in improved end-of-treatment and sustained response rates, with an overall 41% sustained virological response rate in patients treated for 48 weeks. Therapeutic benefit also extends to the traditionally difficult to treat patients (genotype 1, high viral load and advanced fibrosis). The addition of ribavirin to interferon has also resulted in an increased toxicity profile, which has made therapy more difficult for both the patient and managing physician. However, the significant improvement in response rates for all patients makes combination therapy the most appropriate choice as the first- line therapy for suitable patients with chronic viral hepatitis C. Appropriate management with interferon and ribavirin includes assessing the patient's HCV genotype to determine the optimal duration of therapy, assessing therapeutic efficacy by measuring HCV-RNA at 24 weeks and monitoring for the additional ribavirin side-effects. (C) 2000 Blackwell Science Asia Pty Ltd. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1046/j.1440-1746.2000.02082.x | PubMed URL: | 10921409 [http://www.ncbi.nlm.nih.gov/pubmed/?term=10921409] | ISSN: | 0815-9319 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/32932 | Type: | Review | Subjects: | major clinical study male priority journal rash/si [Side Effect] relapse reverse transcription polymerase chain reaction review teratogenicity/si [Side Effect] virus load *interferon/ae [Adverse Drug Reaction] *interferon/cb [Drug Combination] *interferon/do [Drug Dose] *interferon/dt [Drug Therapy] *interferon/pd [Pharmacology] *ribavirin/ae [Adverse Drug Reaction] *ribavirin/cb [Drug Combination] *ribavirin/do [Drug Dose] *ribavirin/dt [Drug Therapy] *ribavirin/pd [Pharmacology] retinopathy/si [Side Effect] antiviral activity diarrhea/si [Side Effect] drug effect female hemolysis/si [Side Effect] *hepatitis C/dt [Drug Therapy] Hepatitis C virus human adult aged immunomodulation insomnia/si [Side Effect] leukopenia/si [Side Effect] liver biopsy immunomodulation insomnia / side effect leukopenia / side effect liver biopsy major clinical study male priority journal rash / side effect relapse retinopathy / side effect aged review teratogenicity / side effect virus load adult reverse transcription polymerase chain reaction antiviral activity diarrhea / side effect drug effect female hemolysis / side effect *hepatitis C / *drug therapy Hepatitis C virus human |
Type of Clinical Study or Trial: | Review article (e.g. literature review, narrative review) |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.